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Introduction: Transarterial chemoembolization (TACE) is indicated for primary hepatic tumours when
resection or local ablation are not feasible. Patients undergoing TACE have a better survival than best
supportive therapy. However, there is paucity of prospective studies on the quality of life (QOL) after TACE
for primary hepatic malignancies, especially in the Western world.
Purpose: The primary aim of the present study was to determine if TACE impacts on the QOL of patients
affected by primary hepatic tumours, and to assess treatment efficacy in a prospective cohort of patients
treated at a tertiary Canadian university medical centre.
Methods: From September 2005 to December 2010, 48 candidates for TACE underwent at least one
TACE session. Data on their QOL, tumour response, serum alpha fetoprotein (AFP) and survival were
prospectively collected every 3–4 months.
Results: The overall QOL of patients undergoing TACE did not decline during the first 12 months after
treatment. A decline was observed in the physical health domain after the third TACE that coincided with
the increasing size of the largest tumour and a rise in the serum AFP levels. Psychological, social and
environmental domains remained stable throughout the treatment period. Multivariate analysis revealed
that tumour focality, AFP levels and model of end-stage liver disease (MELD) scores were associated with
long-term survival (P = 0.001, P = 0.01, P = 0.02, respectively). The overall survival at 12, 36 and 48
months were 72%, 28% and 12%, respectively.
Conclusion: TACE is an effective palliative intervention for unresectable and non-ablatable primary liver
tumours without affecting the QOL of patients even when repeated interventions are performed.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer
in the world and the third most common cause of cancer-related
mortality.1 Although more common in Asia and Africa, its inci-
dence is increasing in the Western world.2 According to the Sur-
veillance and Epidemiology End Results (SEER) registries in the
United States, the average age adjusted incidence of HCC
increased from 1.3 per 100 000 in 1978 to 1980 to 6.6 per 100 000
in 2002.3 Similarly, the incidence of intrahepatic cholangiocarci-
noma is rising in most countries and it represents the second
This manuscript was presented as a poster in the AASLD meeting in San
Francisco, November 2011.
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most common malignancy of the liver after HCC.4 At the time of
diagnosis, the vast majority of patients are not surgical candidates
and palliative modalities such as local ablation and transarterial
chemoembolization (TACE) are the only possible treatments.5
TACE is indicated when a resection or local ablation are not
feasible or for patients waiting for a liver transplantation.6 It
combines the injection of antineoplastic agents with the selective
obstruction of the arteries feeding the tumour causing cell
necrosis while preserving normal liver parenchyma.7 More
recently, TACE has found a role as a neo-adjuvant strategy for
resectable patients with HCC8 and for selected cases of unresec-
table cholangiocarcinoma.9 A partial response has been observed
in 17% to 61.9% of cases,10 although a complete response is very
rare (0%–4.8%).8
As the majority of patients undergoing TACE suffer from a
terminal disease, preventing liver decompensation and maintain-
ing an acceptable quality of life (QOL) during their treatment is as
important as prolonging their survival. In the past decade, only
a few studies, mainly from Asia, have measured the QOL of
patients undergoing TACE for primary hepatic tumours. Asian
patients are well known to have different risk factors than in
Western countries.11–14 Therefore, the main objective of this
prospective study was to assess the impact on the QOL and
survival of patients undergoing sequential sessions of TACE in
a tertiary university hospital in North America.
Patients and methods
Patient population
All patients referred to the Queen Elizabeth II Health Sciences
Centre (Halifax, Nova Scotia, Canada) and diagnosed with unre-
sectable and non-ablatable HCC or cholangiocarcinoma were
considered candidates for this study. Patients affected by HCC
were triaged to their therapeutic algorithm according to the Bar-
celona Clinic Liver Cancer (BCLC) staging criteria.15 Patients with
cholangiocarcinoma were treated with TACE only if unable to
undergo hepatic resection or local ablation for one of the follow-
ing reasons: tumour size, tumour location or the presence of
severe comorbidities. All participants were recruited from hepa-
tology, oncology and surgical clinics. Written consent was
obtained from each participant or from their next of kin when
affected by visual, hearing or other significant cognitive impair-
ments. The local ethic review board approved the study protocol
as it followed the ethical principles for medical research involving
human subjects according to the Declaration of Helsinki devel-
oped by the World Medical Association.
Study design
From September 2005 until December 2010, 48 consecutive
patients who satisfied the inclusion criteria underwent a total of
105 TACE sessions. All participants were presented at a multidis-
ciplinary weekly meeting where medical oncologists, hepatolo-
gists, surgeons and interventional radiologists discussed and
obtained a consensus on the best treatment strategy for each
patient. For patients referred for TACE, the location and number
of suspected primary liver tumours were recorded prospectively.
Multifocal tumours were defined as multiple lesions identified on
imaging tests in several segments of the same hepatic lobe and
bilobar involvement was defined when both hepatic lobes were
involved according to the Brisbane terminology of liver anatomy.16
In the presence of bilobar disease, chemoembolization of the lobe
with the largest tumour burden was performed first followed by
treatment of the contralateral lobe after 3–4 months. QOL ques-
tionnaires, physical examination, radiological abdominal studies
with i.v. contrast injection, chest radiographs and haematological
and chemistry blood tests were obtained per protocol at the time
of diagnosis and then before all TACE procedures. TACEs were
performed every 3 to 4 months by dedicated interventional radi-
ologists unless extrahepatic disease, liver decompensation or sig-
nificant side effects occurred. Patients who had transient liver
decompensation or who developed systemic infection or bone
marrow suppression during the duration of this study were
re-evaluated every 3 to 4 months, or more often if necessary, and
considered candidates for a repeat TACE if they satisfied the origi-
nal inclusion criteria.
All data were prospectively collected by the primary investiga-
tors or by a study coordinator and entered into a digital database
with secure access to protect patients’ confidentiality. Intention-
to-treat analysis of the QOL data was performed by comparing
changes occurring over time to the baseline values obtained prior
to the first intervention.
TACE procedures
All patients underwent TACE according to a standard protocol.
Abdominal contrast computerized tomography (CT) or magnetic
resonance imaging (MRI) studies were obtained within 4 weeks
before each therapeutic intervention.All patients were admitted to
the hospital the night before TACE, fasted overnight and were
required to stay for a minimum of one night after the procedure.
Intravenous (i.v.) fluid hydration and parenteral antibiotic pro-
phylaxis with cefazolin (or vancomycin/clindamycin if allergic)
and metronidazole were administered before arterial groin cath-
eterization. Post TACE all patients received 4–8 mg of i.v.
ondasentron to prevent nausea and vomiting associated with
sedatives and chemotherapy used during the procedure. Patients
affected by viral hepatitis B received lamivudine therapy before
and after TACE to prevent hepatitis flare ups. A selective 4- or
5-French catheter was introduced by cannulating the common
femoral artery and a visceral angiography was carried out to assess
the arterial blood supply to the liver and confirm patency of the
portal vein. Depending on the size, location and arterial supply of
the tumour, the tip of the catheter was advanced into the right or
left hepatic artery or super-selectively when possible using
microcatheters. In super-selective TACEs, the distal portion of
the sub-segmental artery feeding the tumours were injected with
chemotherapy agents and embolized to evoke neoplastic necrosis
on a small area of the liver, thus avoiding damage to normal
342 HPB
HPB 2012, 14, 341–350 © 2012 International Hepato-Pancreato-Biliary Association
parenchyma. Chemoembolization of only one lobe of the liver for
each TACE session was carried out after mixing doxorubicin
hydrochloride (75 mg/m2 body surface area) with 10 ml of lipi-
odol (ethiodized poppy seed oil, EZ-EM®; Montreal, Quebec,
Canada) for patients with HCC and gemcitabine (1500 mg/m2
body surface area) for patients with cholangiocarcinoma. Polyvi-
nyl alcohol particles were then injected if the chemoembolized
artery territory did not show stagnant flow. During the period
between 2009 and 2010, doxorubicin eluting beads were used to
perform TACE in patients affected by HCC who were randomized
in an international multicentric controlled trial comparing drug
eluting beads chemoembolization vs. conventional TACE. Before
discharge, all patients underwent baseline post-treatment CT
without parenteral contrast injection to assess the distribution of
lipiodol in the tumour or with intravenous dye injection to assess
the vascularity of the neoplastic lesions for patients treated with
drug eluting beads.
Primary aim of the study
The primary aim of the present study was to determine if the QOL
of patients undergoing TACE for unresectable and non-ablatable
primary hepatic tumours had a significant decline over time in
comparison with their pre-intervention state.
Secondary aims of the study
The secondary aims of the study were to assess 5-year overall
survival and if there were survival differences according to focal-
ity, lobar distribution, tumour response by response evaluation
criteria in solid tumours (RECIST) criteria and10 variation in
serum AFP levels in all patients undergoing at least one TACE.
Inclusion and exclusion criteria
Patients included in the present study were all adults able to give
written consent or for whom consent was obtained by their next
of kin, affected by non-resectable and non-ablatable HCC or cho-
langiocarcinoma in the presence of compensated liver function
(Child–Pugh A or B)17 with an Eastern Cooperative Oncology
Group (ECOG) performance status between 0 to 218 and without
radiological evidence of extra-hepatic disease.
Patients were excluded if younger than 18 years of age, unable
to provide written consent, affected by advanced liver dysfunction
(Child–Pugh class C) or renal impairment (defined as serum crea-
tinine above 180 mmol/l), allergic to i.v. dye, or when diagnosed
with extra-hepatic disease, with main portal vein (PV) or main
branch PV thrombosis, and if affected by neutropenia (neutrophil
count equal or less than 1000/ml) or thrombocytopenia (platelet
count equal or less than 50 000/ml).
Diagnosis of primary hepatic tumours
A diagnosis of HCC was made when one cross-sectional study
(triphasic contrast abdominal CT scan or MRI) was suggestive
for HCC in the presence of serum AFP above 100 ng/ml. Alterna-
tively, HCC was diagnosed when two contrast-enhanced cross-
sectional studies showed the presence of hypervascular tumours
with portal vein washout. When a diagnosis was not established
using non-invasive modalities, a percutaneous liver biopsy of the
most accessible tumour was obtained according to the guidelines
of the American Association for the Study of Liver Diseases
(AASLD).19 A diagnosis of cholangiocarcinoma was made by
tissue diagnosis obtained by a true cut liver biopsy in all patients
before undergoing TACE.
Variables collected at the time of diagnosis
The following demographic and clinical variables were collected
at the time of enrolment: patients’ age, gender, weight, height,
body mass index (BMI) and body surface area (BSA), which were
used to calculate the amount of chemotherapy agent infused
during each TACE session. Clinical variables included the risk
factors contributing to the development of primary hepatic
tumours, histology when available, the measurement of the main
diameter of the largest tumour nodule, the presence of multicen-
tric or multilobar tumours and the total number of nodules.
Haematological parameters included a coagulation profile, renal
and liver function tests, the model of end-stage liver disease
(MELD) at the time of diagnosis,20 serum AFP levels, the presence
of vascular tumour involvement by radiological characteristics or
by histology, interventions performed before and after each par-
ticipant’s inclusion such as ablation, resection or liver transplan-
tation and the total number of TACE sessions for each patient.
Variables collected during therapy
After the first TACE session, the following variables were collected
at interval of 3–4 months in addition to the quality of life ques-
tionnaires: the size of the largest tumour nodule treated by TACE
on the most recent cross sectional radiology study, hematological
parameters, coagulation profile, renal and liver function tests and
the serum AFP levels.
Quality-of-life questionnaire
Patients were requested to complete the baseline World Health
Organization QOL questionnaire (WHOQOL-BREF)21 fully and
without assistance, and were given adequate time to complete this
task before reviewing their disease status and treatment plan.
Patients were then requested to complete the questionnaire during
each visit scheduled every 3 to 4 months in accordance with the
guidelines set forth in the WHOQOL-BREF Manual. The
WHOQOL-BREF was chosen as the instrument to assess QOL
because it is comprehensive, it has been validated in several coun-
tries, it is easy to administer and it is relatively short in comparison
with other similar instruments. The WHOQOL-BREF contains a
total of 26 questions divided into four domains: physical, psycho-
logical, social and environmental health. Attributes incorporated
within the physical health domain of the WHOQOL-BREF
include: activities of daily living, dependence on medicines or
medical aids, energy and fatigue, mobility, pain and discomfort,
sleep and rest and work capacity. Attributes incorporated within
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the psychological health domain are: body image and appearance,
negative and positive feelings, self-esteem, spirituality, religion
and personal beliefs, thinking, learning, memory and concentra-
tion. Measurements of social health domain include personal
relationships, social support and sexual activity. Features
incorporated in the environmental health domain are: financial
resources, freedom, physical safety and security, health and social
care, home environment, opportunities for acquiring the new
information and skills, participation in and opportunities for
recreation, physical environment and transportation.
Raw scores were scaled in a positive direction (i.e. higher scores
denote higher QOL) then data were transformed in scores on a
0–100 scales using validated conversion.21 Questionnaires
which contained more than 20% of missing data were discarded
as recommended by instruction provided in the manual of
WHOQOL-BREF.
Tumour staging
The largest tumour nodule identified, using contrast cross-
sectional abdominal imaging tests, was sized for each patient at
the time of diagnosis and before each TACE by one of the primary
investigators (K.M.E.). All the measurements were performed
using an electronic scale in millimeters provided by the software
used by the radiology department at our institution (IMPAX
Web1000®; Agfa, Mortsel, Belgium). TNM classification (AJCC,
7th edn)22 was used to stratify tumours according to their largest
diameter.
Follow-up
Every 3–4 months, all patients were evaluated with physical
examinations, chest radiographs, serial radiological studies with
parenteral contrast infusion in addition to haematological and
biochemical tests including serum AFP. Patients were censored if
alive at the time of the closure of the present study, when they had
undergone liver transplantation, or if they were lost at follow-up.
The time of censoring was defined as the last date of documented
follow-up. Missing data were minimized by contacting patients,
their families or their primary physicians by phone or by letters.
Patient’s date of demise was confirmed by death certificate, from
the prospective provincial tumour registry or by contacting
patients’ primary doctors or their next of kin. Follow-up data were
available for all participants.
Statistical analysis
Summary statistics were constructed for the baseline values, using
frequencies and proportions for categorical data, and means and
standard deviations (SD) for continuous variables. Categorical
outcomes were analysed using the chi-square test or Fisher’s exact
test when appropriate. Continuous variables were compared using
theMann–Whitney or Kruskal–Wallis test. All statistical tests were
two-tailed and a P-value of less than 0.05 was considered signifi-
cant. For time-to event outcomes, the distributions of time to the
first event were compared using the log-rank test; the Kaplan–
Meier method was used to estimate the absolute risk of each event
for each group, and hazard ratios and 95% confidence intervals
(CIs) were estimated using the Cox proportional hazardmodel. To
identify the baseline and clinical variables associated with the
overall survival time,multivariable analyses were performed using
the Cox proportional hazard model with a stepwise selection pro-
cedure. The stepwise procedure was set at the threshold of 0.10 for
inclusion and 0.05 for exclusion. Repeated measures analysis of
variance (anova) was performed to test for trends in QOL mea-
sures taken after TACE sessions over time, controlling for baseline
QOL measure taken before the first TACE session. This was done
for each of the four health domains. All statistical analyses were
performed with the intent to treat methods using SPSS 18.0 sta-
tistical software (SPSS Inc., Chicago, IL, USA) or SAS (version 9.2;
SAS Institute Inc., Cary, NC, USA).
Results
Patients' characteristics
Table 1 outlines the demographic and clinical characteristics of
the study population. The mean age of participants was 61.1 years
(SD = 9.0) with the majority being males (87.5%). The most
common predisposing factor of HCC was hepatitis C virus infec-
tion (34.7%) followed by alcoholic cirrhosis (32.7%). Two
patients (4.1%) were diagnosed with unresectable cholangiocar-
cinoma and received gemcitabine9 chemotherapy during their
TACEs.
Chemoembolization treatment
According the patient’s clinical response to TACE and tumor char-
acteristics on CT, the decision was made to proceed for another
TACE session when there was evidence of enhancing viable
tumour without lipiodol deposition, tumour growth or the devel-
opment of new tumours. Five patients (10.4%) were deemed still
transplantable after TACE and underwent cadaveric liver trans-
plants. All patients underwent at least one TACE with 12.5% of
participants undergoing three or more sessions. The median
number of chemoembolizations per patient was 1.7. The time
interval between subsequent TACE procedures was determined
using patient-specific clinical and radiological factors; the mean
interval between TACE 1 and TACE 2 was 18 weeks (SD = 8.0),
and TACE 2 and TACE 3 was 22 weeks (SD = 5.9) (Table 1). Only
two patients had more than 3 TACE sessions (5 and 6 interven-
tions respectively).
The mean size of the treated tumours was 5.2 cm (SD = 3.2)
with a single mass detected in 54.2%. Thirty patients (62.5%)
received TACE for a right lobe HCC whereas 16 (33.3%) received
TACE for bilobar lesions (Table 2). The average MELD score and
AFP levels before the first TACE session were 8.5 (SD = 3.2) and
8775.9 ng/ml (SD = 34 346.4), respectively (Table 2).
Quality-of-life measures
The transformed scores of the WHOQOL-BREF questionnaires
for physical, psychological, social relationships and environmental
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wellbeing domains were obtained at the time of diagnosis and
before each TACE session. The overall trend of each domain was
followed throughout the treatment period controlling for the
baseline QOL measured before the first TACE. There were no
statistically significant temporal trends for any of the four health
domain QOL measures at the alpha = 0.05 level. As represented in
Fig. 1, the overall QOL of patients undergoing repeat sessions of
TACE remained stable over time, although a trend towards a
decline of the physical health domain was observed after patients
underwent at least three interventions (P = 0.08) that coincided
approximately to 1 year after the first treatment.
Tumour response
For most of the patients, there seemed to be a disease-stabilizing
effect on the tumour size by the RECIST criteria10 with a concomi-
tant decline of the serum AFP levels measured at 3, 6, 9 and 12
months. Although not statistically significant, the reduction in
serum AFP and tumour size persisted for 6–9 months after the
first therapy and progression of the disease was observed after the
third session of chemoembolization as represented in Fig. 2.
Survival
The median survival of this cohort was 22 months (95% CI =
16.6–27.3) and the overall survival probability at 12, 36 and 48
Table 1 Study population characteristics
Variable Values
Age, years (SD) 61.1 (9.0)
Gender, male (number, percentage) 42 (87.5)
Risk factors for a primary hepatic tumour
(number, percentage)
Viral hepatitis C 17 (35.4%)
Viral hepatitis B 2 (4.2%)
Non-alcoholic stato-hepatitis 4 (8.3%)
Alcohol 16 (33.3%)
Other 5 (10.4%)
Body mass index (average, SD) 28.3 (5.3)
Body surface area, m2 (average, SD) 1.94 (0.23)
Candidates for liver transplantation
(number, percentage)
21 (43.7%)
Number of patients transplanted
(number, percentage)
5 (10.4%)
Prior interventions for hepatic tumour
(number, percentage)
RFA 6 (12.5%)
Histological diagnosis (number, percentage) 10 (20.8%)
Radiological diagnosis (number, percentage) 38 (79.2%)
Tumour type (number, percentage)
Hepatocellular carcinoma 46 (95.8%)
Intrahepatic cholangiocarcinoma 2 (4.2%)
Total number of TACE procedures 105
Number of TACE procedures per patient (mean, SD) 1.7 (1.0)
Number of tumours per patient (mean, SD) 2.1 (1.6)
Total number of TACE procedures
(number, percentage)
Left lobe 2 (4.2%)
Right lobe 30 (62.5%)
Both lobes 16 (33.3%)
Mean follow-up (months, SD) 12.3 (10.4)
Mean interval between TACE 1 and TACE 2
(weeks, SD)
18 (8.0)
Mean interval between TACE 2 and TACE 3
(weeks, SD)
22 (5.9)
Mean interval between TACE 3 and TACE 4
(weeks, SD)
13 (1.4)
SD, standard deviation; RFA, radiofrequency ablation; TACE, transarterial
chemoembolization.
Table 2 Tumour and laboratory variables at diagnosis
Tumor and laboratory
variables at diagnosis
Value
Tumour characteristics (number, percentage)
Single tumour 26 (54.2%)
Multiple tumours 22 (45.8%)
Size of the largest tumour, cm (mean, SD) 5.2 (3.2)
Location of tumour (number, percentage)
Left lobe 2 (4.2%)
Right lobe 30 (62.5%)
Bilobar 16 (33.3%)
Radiological vascular tumour invasion
(number, percentage)
Present 6 (12.5%)
Absent 42 (87.5%)
TNM classification (AJCC, 7th Edition)
(number, percentage)
T1 10 (20.8%)
T2 15 (31.3%)
T3a 19 (39.5%)
T3b 4 (8.3%)
White blood count ¥ 10(9)/l (mean, SD) 6.1 (2.2)
Red blood cells ¥ 10(120/l (mean, SD) 4.0 (0.5)
Platelets ¥ 10(9)/l (mean, SD) 149 (101.0)
INR (mean, SD) 1.2 (0.2)
Potassium mmol/l (mean, SD) 4.1 (0.4)
Sodium mmol/l (mean, SD) 136 (3.4)
Creatinine mmol/l (mean, SD) 79.6 (20.5)
Total bilirubin mmol/l (mean, SD) 25 (18.8)
Albumin g/l (Mean, SD) 33.5 (4.6)
MELD (mean, SD) 8.5 (3.2)
Serum alpha fetoprotein level (mean, SD) 8 775.9 (34 346.4)
SD, standard deviation; MELD, model of end-stage liver disease.
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months was 72, 28 and 12% respectively (Fig. 3). At univariate
analysis, patients affected by a single tumour vs. multifocal disease
or by involvement of one lobe vs. both lobes had significant better
survival rates after TACE (P < 0.05) (Fig. 4a–b). To determine the
effect of other potential prognostic factors associated with sur-
vival post TACE, a backward stepwise selection in the Cox pro-
portional hazard regression model was performed including
important clinical variables such as: age, tumour size, presence of
multicentric and multilobar disease, vascular invasion, MELD
score and serum AFP. Among them, the presence of multiple
tumours (P = 0.001), a MELD score above 8 (P = 0.01) and serum
AFP levels above 100 ng/ml (P = 0.02) at the time of diagnosis
were all associated with a significantly worse outcome after TACE.
Discussion
Kato and colleagues described TACE for the first time in 1981.23
Although there is consensus in terms of improved tumour
response after TACE, the results on survival benefit remained
controversial until 2002 when two trials demonstrated a
survival advantage for patients undergoing treatment in com-
parison to best supportive care.24,25 A recent systematic review26
has confirmed that TACE improves the overall survival for
patients with unresectable and non-ablatable HCC; however
data on the longitudinal variations of the QOL of subjects
undergoing treatment remains very scarce especially in Western
countries.
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Figure 1 Graphical representation of the trends of the quality of life (QOL) of patients undergoing transarterial chemoembolization (TACE) for
primary hepatic tumours. A repeated measures analysis of variance for the temporal trend of each domain did not reveal any statistical
significance when controlling for the baseline value measured before the first TACE
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Figure 2 Interval changes of the tumour with the largest diameter and levels of serum alpha fetoprotein. Both variables did not show any
statistical difference over time although there was a decline in the serum tumour marker level and the largest diameter of the tumour treated
by TACE (P = NS)
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As the majority of patients with primary hepatic tumours diag-
nosed in Europe and North America are cirrhotic, treatment
modalities are more likely to be dictated by the function of the
liver rather than by the tumour stage. Quite often clinicians taking
care of cirrhotic patients with primary hepatic tumours have to
face the difficult decision to determine if the treatment is worth
the potential risk of provoking liver decompensation with the
possibility of a rapid decline of patients’ QOL, or in the worst case
scenario, causing irreversible organ failure and premature death.
A large body of literature has shown that TACE improves the
overall survival of patients with primary liver tumours who are
not surgical candidates,4,9,25,27 but still there are only a few prospec-
tive studies12,13,28 that have analysed the trend of the QOL of these
patients. None have assessed the potential relationship between
QOL, tumour response and overall survival. Without any doubts,
during the past decade health care providers have been paying
more attention to measuring the QOL of patients undergoing
oncological treatments. Several previous studies have shown that
for patients with terminal diseases, their overall survival might not
be as important as maintaining a good level of functional
status.29–32 In light of these findings, QOL assessment has become
more critical when the likelihood of a cure is low as in advanced
HCC.28 In these circumstances, QOL has been increasingly used as
an outcome measure for the evaluation of different palliative
treatments where the goal is to improve or maintain patients’
ability to live the best possible life within the constraint of their
disease. Unfortunately, for HCC the assessment of QOL has
occurred mostly in the context of randomized controlled trials
testing the safety and the effectiveness of new therapies in com-
parison to the standard therapy already in use and very limited
data is available for patients treated outside these trials.28
Recognizing these limitations,Wible et al.12 have studied a pro-
spective cohort of patients treated with TACE for non-surgical
HCC in the USA. They recruited 73 subjects who underwent 163
surveyed TACE sessions and used the Short Form-36 (SF-36)
Health Survey Forms (Version 1)33 to evaluate potential changes in
the QOL of patients undergoing TACE every 4 months. In this
previous study, patients reported a significant improvement in
their QOL at 4 months after the first TACE although at 8 and 12
months the reported differences of QOL did not reach statistical
significance and became almost non-existent after 1 year. One of
the most important findings was that there was no trend towards
deterioration of patients’ overall QOL over the 12-month period
even if a large proportion of patients had Child–Pugh class B and
C liver dysfunction for whom some deterioration of their QOL
would have been expected for the natural progression of the
tumour and liver disease.
These findings were also confirmed in our study where
the majority of patients had compensated cirrhosis with an
average MELD score of 8. In our population, patients tolerated
selective TACE sessions well and were discharged from the
hospital after only 1 or 2 days during which they were treated for
hydration or pain control. The most common immediate side
effect after TACE was the development of some degree of post-
embolization syndrome that occurred in about 40% to 50% of
patients. Severe side effects such as the development of a hepatic
abscess (one patient) and transient liver decompensation with
the development of ascites responsive to diuretics occurred in
five patients. These findings were similar to previous data
reported by our group.34 In patients with bilobar disease the
decision was made to start with the lobe showing the most
tumour burden and then re-evaluate according to the tumour
response as well as patient’s tolerability to the procedure. A
step-wise approach was performed in order to prevent liver
decompensation which could occur when bilateral simultaneous
TACEs are performed.
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Figure 3 Overall survival after treatment with transarterial chemoembolization (TACE) for primary hepatic tumours
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As previously shown by Wible et al.,12 the most important
finding of the present study was that the majority of patients were
able to tolerate several TACE sessions without significant deterio-
ration of their QOL. The QOL of the cohort remained stable for
almost 1 year whereas a decline was observed only after the third
TACE that coincided with progression of the tumours. The find-
ings of the present study were similar to a recent study by Toro
et al.35 where the QOL of the group of patients receiving TACE
declined 9 months after initiation of therapy. Yet, in this previous
study all aspects of QOL were affected which was more evident on
a longer follow-up period. With this aggressive chemoemboliza-
tion approach, the overall survival of our population at 12, 36 and
48 months were 72%, 28% and 12% respectively. Our results
confirmed that the survival benefit after TACE is observed even
when patients had multiple tumours or bilobar disease although
significantly better long-term survival was seen for patients with
single tumours or multiple tumours involving only one lobe of
the liver.
These findings are in line with the survival outcomes of the two
large randomized controlled trials. Llovet et al.25 reported 2-year
survival rates of 63% for patients undergoing TACE vs. 27% for
best supportive care. Lo et al.24 reported 3-year survival rates of
26% and 3%, respectively. The present study has confirmed that a
reduction in serum AFP,36 repetition of TACEs,37,38 low MELD
score,39 the absence of diffuse disease40,41 and small tumour size42
are all associated with a better prognosis.
One of the limitations of the present study was the relatively
small number of patients and the fact that not all subjects under-
went histological proof of HCC. Therefore, there is the potential
risk that some patients treated with TACE were not affected by
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Figure 4 (a) represents the Kaplan–Meier survival curves of patients affected by single vs. multiple primary hepatic tumours (P = 0.04).
Similarly, in (b), patients with tumour involvement of both hepatic lobes had a significant lower survival rate in comparison with individuals
who had only one lobe involved by tumours (P = 0.02)
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primary malignant lesions of the liver, but rather benign entities
such as adenomas, focal nodular hyperplasia, regenerative or
dysplastic nodules that might appear as HCC by radiological
criteria. Nevertheless, our protocol applied the diagnostic criteria
for HCC suggested by the AASLD in which liver biopsy is not
indicated for the diagnosis of HCC in the presence of confirming
cross-sectional contrast enhanced radiological studies.19
The strength of the present study is that it is the only prospec-
tive observational study designed to assess both the QOL and
overall survival of patients diagnosed with primary hepatic
tumours treated with an aggressive TACE protocol where
chemoembolization was performed every 3–4 months in a North
American population. As patients characteristics are heteroge-
neous in different geographical areas, our study has shown that
even in compensated cirrhotic patients, TACE not only provides
overall survival benefits in comparison to best supportive care, but
also does not impact negatively on their overall QOL.
Another important aspect is that the WHOQOL-BREF ques-
tionnaire was chosen because this instrument has been validated
in several Countries outside North America and Europe and
therefore our results could be generalizable to other geographical
areas where socio-economic and patients’ characteristics differ
from our sample. In addition, it could be used for future studies
to confirm or reject our findings in countries where the risk
factors for primary liver tumours differ significantly from our
population.
In summary, TACE for the treatment of primary unresectable
hepatic neoplasms is a safe and effective therapy that prolongs life
even in cirrhotic patients with compensated liver disease. It does
not seem to negatively impact their QOL even when repeated
treatments are performed formultiple liver tumours or for bilobar
disease.
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